Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Neoplasms, Germ Cell and Embryonal 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Hepatoblastoma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Malignant Peripheral Nerve Sheath Tumors 1Ototoxicity 1Oligodendroglioma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroblastoma × Vorinostat × 1 year × Clear all
NCT02559778 2026-04-28

PEDS-PLAN

Milton S. Hershey Medical Center

Phase 2 Recruiting
500 enrolled
CNS

Neuroblastoma

NCT04308330 2026-04-15

NYMC195

New York Medical College

Phase 1 Recruiting
30 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT07261241 2025-12-03

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Not yet recruiting
118 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡